Adma Biologics (ADMA) Shares Outstanding (2011 - 2026)

Adma Biologics (ADMA) has 15 years of Shares Outstanding (Entity) data on file, last reported at $239.8 million in Q4 2025.

• Quarterly Shares Outstanding (Entity) rose 1.34% year-over-year to $239.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $239.8 million (up 1.34% YoY) and the FY2025 annual result came in at $239.8 million, up 1.34% from the prior year.
• Shares Outstanding (Entity) was little changed at $239.8 million in Q4 2025, from $239.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $239.8 million in Q4 2025 to a low of $123.0 million in Q1 2021.
• A 5-year average of $206.9 million and a median of $225.2 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) surged 62.03% — and 2025, when it climbed 1.34%.
• Tracing ADMA's Shares Outstanding (Entity) over 5 years: stood at $139.6 million in 2021, then surged by 58.92% to $221.8 million in 2022, then advanced by 1.91% to $226.1 million in 2023, then grew by 4.67% to $236.6 million in 2024, then gained by 1.34% to $239.8 million in 2025.
• The last three Shares Outstanding (Entity) figures came in at $239.8 million (Q4 2025), $239.7 million (Q3 2025), and $239.4 million (Q2 2025), per Business Quant data.